Comparative Pharmacology
Head-to-head clinical analysis: CYLERT versus DEXEDRINE SPANSULE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYLERT versus DEXEDRINE SPANSULE.
CYLERT vs DEXEDRINE SPANSULE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CNS stimulant; increases extracellular dopamine and norepinephrine levels by blocking their reuptake and enhancing release.
Dextroamphetamine is a central nervous system (CNS) stimulant that increases synaptic concentrations of norepinephrine and dopamine by blocking their reuptake and promoting release from presynaptic terminals.
37.5 mg orally once daily in the morning; may increase by 18.75 mg weekly to a maximum of 112.5 mg/day.
5-60 mg orally once daily in the morning, using extended-release capsules.
None Documented
None Documented
Terminal elimination half-life is 12-30 hours in children (mean 19 hours) and 8-14 hours in adults; the long half-life supports once-daily dosing, but accumulation can occur with repeated dosing
Terminal elimination half-life is 6-8 hours in adults, 10-13 hours in children, and prolonged in alkaline urine (up to 16-20 hours) due to enhanced tubular reabsorption. In hepatic impairment, half-life may extend to 12-15 hours. Steady-state is reached within 2-3 days.
Primarily renal (80-90% as unchanged drug and metabolites, with 50-60% as unchanged pemoline), minor biliary/fecal elimination (<10%)
Renal excretion of unchanged drug (approximately 30-40% unchanged) and hepatic metabolism to inactive metabolites (primarily hippuric acid, benzoic acid, and hydroxylated derivatives). About 90% of a dose is excreted in urine within 48 hours, with 10-15% as unchanged dextroamphetamine; minor biliary/fecal elimination (<5% total).
Category C
Category C
CNS Stimulant
CNS Stimulant